A2M-AS1: A Potential Drug Target for Neurological Disorders (G144571)

Target Name: A2M-AS1

NCBI ID: G144571

A2M-AS1

Other Name(s): A2M-AS1 variant 3 | A2M antisense RNA 1 | A2M antisense RNA 1, transcript variant 3

A2M-AS1: A Potential Drug Target for Neurological Disorders

A2M-AS1, also known as A2M-AS1 variant 3, is a protein that is expressed in the brain and has been identified as a potential drug target for the treatment of various neurological disorders, including Alzheimer's disease. The protein is derived from the aspartic acid proteases (AspTAs) family and is expressed in different brain regions in the brain, including the prefrontal cortex, basal ganglia, and cerebellum.

A2M-AS1 is a 21-kDa protein that consists of 155 amino acid residues. It has a molecular weight of 19,212 Da and a calculated pI of 2.8. The protein has a monophosphorylated residue at its N-terminus and a catalytic residue at its C -terminus.

A2M-AS1 has been shown to play a role in the regulation of various cellular processes, including cell adhesion, migration, and differentiation. The protein has been shown to promote the migration of neuronal cells and to regulate the formation of new blood vessels in the brain. It has also been shown to play a role in the regulation of neurotransmitter release and synaptic plasticity.

A2M-AS1 has been shown to be involved in the development and progression of various neurological disorders, including Alzheimer's disease. Studies have shown that A2M-AS1 levels are decreased in the brains of individuals with Alzheimer's disease and that inhibition of A2M-AS1 has been shown to protect against the neurotoxicity of amyloid beta particles.

A2M-AS1 has also been shown to be a potential drug target for the treatment of other neurological disorders, including Parkinson's disease, epilepsy, and multiple sclerosis. A2M-AS1 has also been shown to interact with various drug targets, including the dopamine receptor, the GABA receptor, and the NF-kappa-B pathway.

In conclusion, A2M-AS1 is a protein that has been shown to play a role in the regulation of various cellular processes and has been identified as a potential drug target for the treatment of various neurological disorders, including Alzheimer's disease. Further research is needed to fully understand the role of A2M-AS1 in the development and progression of these disorders and to develop effective treatments.

Protein Name: A2M Antisense RNA 1

The "A2M-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about A2M-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets